Restless Legs Syndrome Clinical Trial
— (CR-RLS)Official title:
A 12-Week, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Flexible Dose Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome (RLS) in RLS Patients With Sleep Disturbance and Periodic Limb Movements (PLM) During Sleep
Verified date | October 2016 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess the efficacy and safety of ropinirole CR-RLS in the treatment of patients with Restless Legs Syndrome and associated sleep disturbance and period limb movements during sleep.
Status | Completed |
Enrollment | 39 |
Est. completion date | June 2007 |
Est. primary completion date | June 2007 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 79 Years |
Eligibility |
Inclusion criteria: - provided written informed consent. - Diagnosed with primary RLS using the International RLS Study Group Diagnostic Criteria with a total score of 20 or greater on the International RLS (IRLS) Rating Scale and significant sleep disturbance indicated on Item 4 of the IRLS rating scale. - Have evening and nighttime symptoms of RLS, significant sleep impairment due to RLS symptoms, and symptoms requiring treatment prior to bedtime, but no earlier than 5:00PM. - Sleep efficiency <85% OR Latency to persistent sleep >20 minutes. Exclusion criteria: - Secondary RLS - Primary sleep disorder - Have any medical conditions that may impact efficacy assessments or that may present a safety concern. - Pregnant or lactating or women of child-bearing potential who are not practicing an acceptable method of birth control. - Use of any prohibited medication. |
Country | Name | City | State |
---|---|---|---|
United States | GSK Investigational Site | Anaheim | California |
United States | GSK Investigational Site | Atlanta | Georgia |
United States | GSK Investigational Site | Auburn | Maine |
United States | GSK Investigational Site | Austell | Georgia |
United States | GSK Investigational Site | Baton Rouge | Louisiana |
United States | GSK Investigational Site | Brandon | Florida |
United States | GSK Investigational Site | Brighton | Massachusetts |
United States | GSK Investigational Site | Charlotte | North Carolina |
United States | GSK Investigational Site | Cincinnati | Ohio |
United States | GSK Investigational Site | Cleveland | Ohio |
United States | GSK Investigational Site | Columbia | South Carolina |
United States | GSK Investigational Site | Corvallis | Oregon |
United States | GSK Investigational Site | Crestview Hills | Kentucky |
United States | GSK Investigational Site | Dallas | Texas |
United States | GSK Investigational Site | Danville | Indiana |
United States | GSK Investigational Site | Dublin | Ohio |
United States | GSK Investigational Site | Duncansville | Pennsylvania |
United States | GSK Investigational Site | Elk Grove Village | Illinois |
United States | GSK Investigational Site | Greenville | North Carolina |
United States | GSK Investigational Site | Greenwood | Colorado |
United States | GSK Investigational Site | Jasper | Alabama |
United States | GSK Investigational Site | Lafayette | Louisiana |
United States | GSK Investigational Site | Lafayette Hill | Pennsylvania |
United States | GSK Investigational Site | Las Vegas | Nevada |
United States | GSK Investigational Site | Lenexa | Kansas |
United States | GSK Investigational Site | Lexington | Kentucky |
United States | GSK Investigational Site | Little Rock | Arkansas |
United States | GSK Investigational Site | Louisville | Kentucky |
United States | GSK Investigational Site | Macon | Georgia |
United States | GSK Investigational Site | Normal | Illinois |
United States | GSK Investigational Site | Oklahoma City | Oklahoma |
United States | GSK Investigational Site | Pembroke Pines | Florida |
United States | GSK Investigational Site | Phoenix | Arizona |
United States | GSK Investigational Site | Portland | Oregon |
United States | GSK Investigational Site | Portland | Oregon |
United States | GSK Investigational Site | San Antonio | Texas |
United States | GSK Investigational Site | San Diego | California |
United States | GSK Investigational Site | St. Louis | Missouri |
United States | GSK Investigational Site | St. Petersburg | Florida |
United States | GSK Investigational Site | Toms River | New Jersey |
United States | GSK Investigational Site | Topeka | Kansas |
United States | GSK Investigational Site | Tulsa | Oklahoma |
United States | GSK Investigational Site | Tuscaloosa | Alabama |
United States | GSK Investigational Site | Walla Walla | Washington |
United States | GSK Investigational Site | Wheat Ridge | Colorado |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in the Periodic Limb Movements in Sleep associated with Arousal/hour of sleep (PLMAI) at Week 12 Change from baseline in sleep Latency at Week 12. | 12 Weeks | ||
Secondary | Assess safety, tolerability, polysomnography efficacy measures, and patient reported outcomes. | 12 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04786314 -
The Effect of Hot and Cold Water Application on Pregnant Women With Restless Leg Syndrome
|
N/A | |
Completed |
NCT01455012 -
Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome
|
Phase 4 | |
Terminated |
NCT01192503 -
Safety and Efficacy of Rasagiline in Restless Legs Syndrome
|
Phase 2/Phase 3 | |
Completed |
NCT00721279 -
Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome
|
N/A | |
Completed |
NCT00530530 -
ASP8825 - Study in Patients With Restless Legs Syndrome
|
Phase 2 | |
Completed |
NCT00375284 -
A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS
|
Phase 4 | |
Completed |
NCT00942253 -
Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)
|
Phase 2 | |
Completed |
NCT00479531 -
Sequential Compression Devices for Treatment of Restless Legs Syndrome
|
Phase 3 | |
Recruiting |
NCT05581576 -
Pitolisant in Refractory Restless Legs Syndrome
|
Phase 4 | |
Active, not recruiting |
NCT03218969 -
Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist
|
Phase 1/Phase 2 | |
Recruiting |
NCT04144790 -
Impact of Iron Supplementation Treatment on Brain Iron Concentrations
|
||
Completed |
NCT05787080 -
Massage, Oxidative and Antioxidant Enzymes in Hemodialysis Patients With Restless Legs Syndrome(RLS)
|
N/A | |
Not yet recruiting |
NCT05529095 -
Sublingual Apomorphine in Refractory Restless Legs Syndrome
|
Phase 4 | |
Recruiting |
NCT05044520 -
Clinical Features Associated With Restless Legs Syndrome.
|
||
Withdrawn |
NCT03849001 -
Impact of Acute Leg Cycling at Various Intensities on RLS Severity in Persons With MS
|
N/A | |
Completed |
NCT03076541 -
Cardiovascular Variability, Heart Rate Response, and Electromyogram Power Associated With Periodic Leg Movements.
|
N/A | |
Recruiting |
NCT04145674 -
A Proof of Concept, Phase 2, Double-blind, Randomized Trial With d-Methadone Product Versus Placebo
|
Phase 2 | |
Completed |
NCT02532608 -
Infra-slow Oscillations During Sleep
|
N/A | |
Completed |
NCT01528462 -
Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke
|
||
Completed |
NCT00748098 -
Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance
|
Phase 3 |